AstraZeneca PLC (AZNN) - Total Liabilities

Latest as of December 2025: MX$65.36 Billion MXN ≈ $3.76 Billion USD

Based on the latest financial reports, AstraZeneca PLC (AZNN) has total liabilities worth MX$65.36 Billion MXN (≈ $3.76 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

AstraZeneca PLC - Total Liabilities Trend (2014–2025)

This chart illustrates how AstraZeneca PLC's total liabilities have evolved over time, based on quarterly financial data. See AZNN working capital ratio to evaluate short-term liquidity relative to the company's equity base.

AstraZeneca PLC Competitors by Total Liabilities

The table below lists competitors of AstraZeneca PLC ranked by their total liabilities.

Company Country Total Liabilities
Agricultural Bank of China Ltd Class A
SHG:601288
China CN¥47.73 Trillion
Palantir Technologies Inc.
NASDAQ:PLTR
USA $1.64 Billion
Morgan Stanley
SA:MSBR34
Brazil R$1.25 Trillion
LVMH Moët Hennessy - Louis Vuitton Société Européenne
PA:MC
France €74.70 Billion
General Electric Company
SA:GEOO34
Brazil R$110.15 Billion
Royal Bank of Canada
TO:RY
Canada CA$2.19 Trillion
Industrial and Commercial Bank of China Ltd
SHG:601398
China CN¥51.42 Trillion
AstraZeneca PLC
NASDAQ:AZN
USA $66.63 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down AstraZeneca PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AstraZeneca PLC market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.94 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.34 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.57 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how AstraZeneca PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for AstraZeneca PLC (2014–2025)

The table below shows the annual total liabilities of AstraZeneca PLC from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 MX$65.36 Billion
≈ $3.76 Billion
+3.47%
2024-12-31 MX$63.16 Billion
≈ $3.64 Billion
+1.95%
2023-12-31 MX$61.95 Billion
≈ $3.57 Billion
+4.25%
2022-12-31 MX$59.42 Billion
≈ $3.42 Billion
-10.07%
2021-12-31 MX$66.08 Billion
≈ $3.80 Billion
+29.33%
2020-12-31 MX$51.09 Billion
≈ $2.94 Billion
+9.21%
2019-12-31 MX$46.78 Billion
≈ $2.69 Billion
+0.37%
2018-12-31 MX$46.61 Billion
≈ $2.68 Billion
-0.22%
2017-12-31 MX$46.71 Billion
≈ $2.69 Billion
+1.86%
2016-12-31 MX$45.86 Billion
≈ $2.64 Billion
+10.37%
2015-12-31 MX$41.55 Billion
≈ $2.39 Billion
+6.67%
2014-12-31 MX$38.95 Billion
≈ $2.24 Billion
--

About AstraZeneca PLC

MX:AZNN Mexico Drug Manufacturers - General
Market Cap
$290.50 Billion
MX$5.05 Trillion MXN
Market Cap Rank
#56 Global
#2 in Mexico
Share Price
MX$1628.00
Change (1 day)
+1.25%
52-Week Range
MX$1289.81 - MX$1722.60
All Time High
MX$1751.39
About

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more